Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452-8.
机构：[1]Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA[2]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院
第一作者机构：[1]Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA[2]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China
通讯作者：
通讯机构：[1]Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA[*1]Therapeutic Radiology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
推荐引用方式(GB/T 7714)：
Liang Jiayu,Beckta Jason M,Bindra Ranjit S.Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452-8.[J].European urology.2019,76(4):e109-e110.doi:10.1016/j.eururo.2019.04.041.
APA：
Liang Jiayu,Beckta Jason M&Bindra Ranjit S.(2019).Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452-8..European urology,76,(4)
MLA：
Liang Jiayu,et al."Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452-8.".European urology 76..4(2019):e109-e110
医学